Windtree Therapeutics Delisting: Nasdaq Rule Violation Leads to Market Volatility

The biotechnology firm, Windtree Therapeutics, has been delisted from the Nasdaq Stock Exchange due to failing to maintain a minimum bid price of $1 for 30 consecutive business days. This breach of Listing Rule 5550(a)(2) has resulted in a significant drop in their stock value and a move to OTC trading markets. The delisting raises concerns about Windtree’s future while the broader cryptocurrency market remains largely unaffected by the event.